The 2019 Medicare formulary landscape represented a significant period of transition for seniors and individuals with disabilities navigating prescription drug coverage. During this year, the Centers for Medicare & Medicaid Services (CMS) continued its push toward greater transparency and value-based care within the Medicare Part D program. This specific formulary year required beneficiaries to understand not just their drug lists, but also the intricate rules governing coverage phases and cost-sharing structures that defined that era.
Understanding the Medicare Part D Formulary System
A Medicare formulary is essentially a curated list of prescription drugs that a specific plan agrees to cover for its members. For the 2019 plan year, these formularies were not static; they were dynamic documents subject to change during the Annual Enrollment Period and, more importantly, during the Fall Open Enrollment period that concluded in December 2018 for coverage starting January 1, 2019. Every Medicare Part D plan and Medicare Advantage Prescription Drug (MA-PD) plan operates with its own distinct formulary, categorized into different tiers that dictate the co-pay or co-insurance costs for each medication.
Drug Tiers and Cost-Sharing in 2019
Typically, formularies are divided into at least four to five tiers, each associated with a different cost level. In 2019, Tier 1 generally consisted of preferred generic drugs with the lowest co-pays, while Tier 2 included non-preferred generics. Tier 3 was often where brand-name drugs resided, requiring higher co-insurance. The critical Tier 4, known as the specialty tier, housed high-cost medications such as biologics and certain chronic disease treatments, which frequently involved significant co-insurance percentages rather than flat co-pays. Beneficiaries were advised to check if their specific medications, especially newer therapies, fell into these higher tiers to avoid unexpected financial burdens.
The Coverage Gap (Donut Hole) in 2019
The Medicare coverage gap, commonly referred to as the "donut hole," remained a crucial consideration for Part D members in 2019. Once a beneficiary and their plan had spent a combined total of $3,820 on covered drugs in 2019, they would enter this gap阶段. While in the donut hole, individuals were responsible for a larger portion of drug costs. However, it is important to note the ongoing improvements to this phase; the 2019 gap saw a reduction in beneficiary cost-sharing for brand-name drugs, with plans required to cover 25% of the cost for both the brand and generic drugs purchased within the gap, a step toward its ultimate closure by 2020.
Out-of-Pocket Maximum and True-Out
An essential safety net within the 2019 formulary structure was the catastrophic coverage phase, which began after a beneficiary reached the out-of-pocket maximum. For the 2019 plan year, this limit was set at $6,550. Once a member hit this threshold, they were responsible only for a small co-payment for covered drugs for the remainder of the year. Furthermore, the concept of "true-out" was significant; this occurred when a beneficiary's total drug spending, including both what they paid and what their plan spent, reached a set threshold (approximately $5,000 in 2019), relieving them of catastrophic costs for the rest of the year regardless of the drug list.
Formulary Management and Utilization Reviews
Beyond listing drugs, the 2019 Medicare formulary involved complex management strategies employed by plan sponsors to control costs and ensure appropriate medication use. Prior authorization was a common tool, requiring a physician to obtain approval from the plan before prescribing a specific medication. Additionally, step therapy protocols might mandate that a patient try and fail on a lower-cost, alternative medication before the plan would cover a more expensive, brand-name drug. These clinical management practices were a primary reason why a drug available on one formulary might be denied or require additional paperwork on another.
